SMS Pharmaceuticals Posts Consistent Growth as API Portfolio Drives Revenue Up 6% YoY
SMS Pharmaceuticals Limited, a diversified and integrated pharmaceutical company specializing in Active Pharmaceutical Ingredients (API) and complex Intermediates, reported unaudited financial results for the quarter ending June 30, 2026. The company demonstrated broad-based growth across its high-value API portfolio while maintaining strong margins.The Executive Director, P. Vamsi Krishna, stated that FY27 commenced strongly with diversified growth in the high-value API sector and an EBITDA margin sustained at approximately 20%. This performance was attributed to backward integration and an improving product mix, which reinforced structural...